Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial

J. Bartlett; P. Canney; A. Campbell; D. Cameron; J. Donovan; J. Dunn; H. Earl; A. Francis; P. Hall; V. Harmer; H. Higgins; L. Hillier; C. Hulme; L. Hughes-Davies; A. Makris; A. Morgan; C. McCabe; S. Pinder; C. Poole; D. Rea; N. Stallard; R. Stein

doi:10.1016/j.clon.2012.10.005

Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial

J. Bartlett, P. Canney, A. Campbell, D. Cameron, J. Donovan, J. Dunn, H. Earl, A. Francis, P. Hall, V. Harmer, H. Higgins, L. Hillier, C. Hulme, L. Hughes-Davies, A. Makris, A. Morgan, C. McCabe, S. Pinder, C. Poole, D. ReaN. Stallard, R. Stein^*

^*Corresponding author for this work

Cancer Clinical Trials Unit

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

Original language	English
Pages (from-to)	109-116
Number of pages	8
Journal	Clinical Oncology
Volume	25
Issue number	2
DOIs	https://doi.org/10.1016/j.clon.2012.10.005
Publication status	Published - 1 Feb 2013

Keywords

Adjuvant
Breast
Chemotherapy
Predictive

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clon.2012.10.005

Cite this

Bartlett, J., Canney, P., Campbell, A., Cameron, D., Donovan, J., Dunn, J., Earl, H., Francis, A., Hall, P., Harmer, V., Higgins, H., Hillier, L., Hulme, C., Hughes-Davies, L., Makris, A., Morgan, A., McCabe, C., Pinder, S., Poole, C., ... Stein, R. (2013). Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. Clinical Oncology, 25(2), 109-116. https://doi.org/10.1016/j.clon.2012.10.005

@article{947f0850a2cc4c94a57609742221659a,

title = "Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial",

abstract = "The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.",

keywords = "Adjuvant, Breast, Chemotherapy, Predictive",

author = "J. Bartlett and P. Canney and A. Campbell and D. Cameron and J. Donovan and J. Dunn and H. Earl and A. Francis and P. Hall and V. Harmer and H. Higgins and L. Hillier and C. Hulme and L. Hughes-Davies and A. Makris and A. Morgan and C. McCabe and S. Pinder and C. Poole and D. Rea and N. Stallard and R. Stein",

year = "2013",

month = feb,

day = "1",

doi = "10.1016/j.clon.2012.10.005",

language = "English",

volume = "25",

pages = "109--116",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier",

number = "2",

}

Bartlett, J, Canney, P, Campbell, A, Cameron, D, Donovan, J, Dunn, J, Earl, H, Francis, A, Hall, P, Harmer, V, Higgins, H, Hillier, L, Hulme, C, Hughes-Davies, L, Makris, A, Morgan, A, McCabe, C, Pinder, S, Poole, C, Rea, D, Stallard, N & Stein, R 2013, 'Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial', Clinical Oncology, vol. 25, no. 2, pp. 109-116. https://doi.org/10.1016/j.clon.2012.10.005

TY - JOUR

T1 - Selecting Breast Cancer Patients for Chemotherapy

T2 - The Opening of the UK OPTIMA Trial

AU - Bartlett, J.

AU - Canney, P.

AU - Campbell, A.

AU - Cameron, D.

AU - Donovan, J.

AU - Dunn, J.

AU - Earl, H.

AU - Francis, A.

AU - Hall, P.

AU - Harmer, V.

AU - Higgins, H.

AU - Hillier, L.

AU - Hulme, C.

AU - Hughes-Davies, L.

AU - Makris, A.

AU - Morgan, A.

AU - McCabe, C.

AU - Pinder, S.

AU - Poole, C.

AU - Rea, D.

AU - Stallard, N.

AU - Stein, R.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

AB - The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays.

KW - Adjuvant

KW - Breast

KW - Chemotherapy

KW - Predictive

UR - http://www.scopus.com/inward/record.url?scp=84872403625&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2012.10.005

DO - 10.1016/j.clon.2012.10.005

M3 - Article

C2 - 23267818

AN - SCOPUS:84872403625

SN - 0936-6555

VL - 25

SP - 109

EP - 116

JO - Clinical Oncology

JF - Clinical Oncology

IS - 2

ER -

Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this